Loading
Cancer, Lipids, and Metabolism / Immune Cells in Cancer / Cancer Research and Treatments · Journal article
Diseases · August 14, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review proposing that tumor-driven pro-inflammatory responses promote cancer growth and that anti-inflammatory drugs could serve as adjuncts to immunotherapy. The source presents a conceptual framework and discusses a range of anti-inflammatory agents (glucocorticoids, NSAIDs, antihistamines, statins, cytokine inhibitors, and others) but provides no original clinical or preclinical data, trial results, or quantitative evidence to support efficacy or safety in cancer treatment.
Journal article.
Pro-tumor inflammation enhances blood flow and nutrient supply, promoting activation of dormant cancer cells Anti-tumor inflammation hinders blood flow and can force active cancer cells into dormancy Tumors actively shift the inflammatory balance toward pro-tumor states to support growth
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review raises a conceptual question about the role of anti-inflammatory therapy in cancer treatment but does not provide evidence sufficient to guide clinical practice. Readers should regard this as a position paper advocating for research rather than as a synthesis of established efficacy data.
A narrative review proposing a conceptual framework linking tumor-driven inflammation to growth and advocating anti-inflammatory therapy, but presenting no new empirical data, clinical trials, or quantitative evidence to support the claims.
This review raises a conceptual question about the role of anti-inflammatory therapy in cancer treatment but does not provide evidence sufficient to guide clinical practice. Readers should regard this as a position paper advocating for research rather than as a synthesis of established efficacy data.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Inflammation can either encourage or suppress tumor growth, thus having a two-sided effect on cancer development. This depends on the balance between pro-tumor and anti-tumor immune responses within the tumor microenvironment (TME). Pro-tumor inflammation, driven by specific immune cells, enhances blood flow and nutrient supply to tumors, promoting the activation of dormant cancer cells (DCCs). Conversely, antitumor inflammation hinders blood flow and can force active cancer cells into a state of dormancy. Tumors actively shift this balance towards pro-tumor inflammation to create a favorable environment for growth. Therefore, anti-inflammatory therapy may be an integral part of comprehensive cancer immunotherapy. This review explores how different anti-inflammatory medications, such as glucocorticoids, non-steroidal anti-inflammatory drugs (NSAIDs), antihistamines, anti-leukotrienes, statins, drugs that block pro-inflammatory cytokines, agents that inhibit oxidative phosphorylation, antioxidant vitamins, anti-angiogenic drugs, and low-dose chemotherapy, can be used to combat cancer. Granulocyte counts and erythrocyte sedimentation rate (ESR) can be used to assess inflammation levels and the effectiveness of anti-inflammatory treatments. We advocate for a paradigm shift in cancer treatment, moving away from aggressive tumor destruction, which triggers uncontrolled tumor regeneration, toward long-term immunological control of tumor growth while preserving the patient’s overall health.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.